secwatch.observer — SEC 8-K summary
======================================

Issuer:     CYPHERPUNK TECHNOLOGIES INC. (CYPH)
CIK:        0001509745
Form:       8-K
Filed at:   2023-01-23T23:59:59+00:00
Accession:  0001104659-23-005803
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.90
Item codes: 1.01, 5.03, 2.01, 3.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Leap Therapeutics acquires Flame Biosciences in merger, issuing ~19.8M shares and Series X Preferred
--------------------------------------------------------------------------------

- Acquired Flame Biosciences for approx 19.8M common shares and 136,833 Series X Convertible Preferred shares.
- Flame stock options cancelled; outstanding warrants assumed and converted into Leap warrants.
- Appointed Patricia Martin and Christian Richard as new non-employee directors.
- Will hold special stockholder meeting to approve conversion of Series X Preferred into common shares.
- Entered into support agreements with HealthCare Ventures IX and HealthCare Ventures VIII.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1509745/000110465923005803/0001104659-23-005803-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1509745/000110465923005803/tm233885d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-005803

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer